Vanda Pharmaceuticals Inc. (VNDA)

Vanda Pharmaceuticals' stock price has been impacted by several events. The company announced its Q3 2025 earnings, reporting an EPS of -$0.38, missing the consensus estimate of -$0.31. The FDA lifted a partial clinical hold on Tradipitant for motion sickness. Vanda submitted a Biologics License Application (BLA) to the FDA for Imsidolimab for the treatment of Generalized Pustular Psoriasis. The FDA approved NEREUS™ (tradipitant) for the prevention of vomiting induced by motion. Vanda announced the receipt of an FDA decision letter on HETLIOZ® Supplemental New Drug Application (sNDA) for jet lag disorder, stating it was not approvable. The Pomerantz Law Firm issued multiple investor alerts regarding claims on behalf of Vanda Pharmaceuticals Inc. investors. Vanda Pharmaceuticals announced it would release its Fourth Quarter and Full Year 2025 financial results on February 11, 2026. The PDUFA target action date for the Bysanti NDA for bipolar I disorder and schizophrenia is anticipated.

The demand for Vanda Pharmaceuticals' therapies is generally expected to be stable rather than highly seasonal, due to the chronic nature of the conditions they address, such as Non-24-Hour Sleep-Wake Disorder, schizophrenia, and multiple sclerosis. While Tradipitant for motion sickness might see some seasonal fluctuations related to travel, the core revenue drivers are for ongoing medical treatments.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for high unmet medical needs, particularly in central nervous system disorders and rare diseases. Their commercial portfolio includes HETLIOZ for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis Syndrome, Fanapt for bipolar I disorder and schizophrenia, and PONVORY for relapsing forms of multiple sclerosis. The company also has a pipeline of products in development, such as Tradipitant for motion sickness, Bysanti for bipolar I disorder and schizophrenia, and Imsidolimab for generalized pustular psoriasis.

Vanda Pharmaceuticals primarily sells its products in the United States, with a market presence also in Israel, Europe, and Canada. The company's headquarters are located in Washington, D.C., USA.

Vanda Pharmaceuticals' brand reputation has been subject to both positive and negative influences, with a news sentiment score of 0.50, lower than the average for Medical companies. The FDA approval of NEREUS™ (tradipitant) for motion sickness was a significant positive event. The FDA's rejection of the HETLIOZ® sNDA for jet lag disorder and investor alerts from the Pomerantz Law Firm had a negative impact on the company's reputation.

Vanda Pharmaceuticals Inc. has a diverse ownership base, heavily dominated by institutional investors. Institutional investors hold approximately 72% to 75.56% of the company's stock, with major holders including BlackRock, Inc. and Vanguard Group Inc. Individual investors hold about 17.08% of the shares. Insiders, including company executives and directors, hold approximately 7.36% of the stock, with Mihael H. Polymeropoulos being a notable individual owner.